FibroGen, Inc. is a company in the U.S. stock market and it is a holding in 62 U.S.-traded ETFs. FGEN has around 7.0M shares in the U.S. ETF market. The largest ETF holder of FGEN is the First Trust NYSE Arca Biotechnology Index Fund (FBT), with approximately 1.53M shares. Investors may also find of interest that the ETF with the largest allocation to FGEN stock is ALPS Medical Breakthroughs ETF (SBIO), with a portfolio weight of 3.15%. On average, U.S. ETFs allocate 0.35% of FGEN to their portfolios.
Additionally, FGEN is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with FGEN as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 27.53%.